[Clinically manifest liver lesions during use of simvastatin].
Symptomatic hepatic damage was diagnosed in six patients, three males and three females, during treatment with simvastatin. All patients recovered after discontinuation of the drug. One patient used the drug again, which led to another increase of serum liver enzyme activity. The period between the start of the treatment with simvastatin and the first symptoms of hepatic damage varied between 1 month and 3 years. If serum liver enzyme activities increase in patients using simvastatin, a causative relation should be considered.
Koornstra
J J
JJ
Medisch Spectrum Twente, afd. Interne Geneeskunde, Enschede.
Ottervanger
J P
JP
Fehmers
M C
MC
Stricker
B H
BH
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007565:Jaundice / Q000139:chemically induced; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D019821:Simvastatin
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin; D019821:Simvastatin
Klinisch manifeste leverbeschadiging tijdens gebruik van simvastatine.